FDA OKs faster-acting insulin aspart for pump use

A rapid-acting version of insulin aspart (Fiasp—Novo Nordisk) has been approved by FDA for use in insulin pumps. This new U.S. indication is for use in insulin pumps in adults with type 1 or type 2 diabetes. Injectable and I.V. forms of insulin aspart injection were first approved in the United States in 2017.

A rapid-acting version of insulin aspart (Fiasp—Novo Nordisk) has been approved by FDA for use in insulin pumps. This new U.S. indication is for use in insulin pumps in adults with type 1 or type 2 diabetes. Injectable and I.V. forms of insulin aspart injection were first approved in the United States in 2017. Rapid-acting aspart features the addition of niacinamide (vitamin B3) to help increase insulin absorption. For mealtime use, it is indicated to be dosed at the beginning of a meal or within 20 minutes of starting a meal, and appears in the blood about 2.5 minutes after dosing. FDA's label expansion decision was based on data from ONSET 5, a randomized, multicenter, multinational trial that compared the efficacy and safety of continuous subcutaneous insulin infusion of rapid-acting aspart with that of regular insulin aspart in adults with type 1 diabetes.